Psilocybin impairs the ability to reproduce time intervals longer than 2.5 seconds, to synchronize movements to beats longer than 2 seconds, and slows preferred tapping rate. These objective timing deficits are accompanied by working-memory impairments and subjective changes including depersonalization and derealization. The findings indicate the serotonin system is selectively involved in processing durations longer than 2–3 seconds and in voluntary movement speed control. The disruption of longer intervals likely results from interactions with cognitive dimensions of temporal processing via 5-HT2A receptor stimulation.
Psilocybin, a hallucinogen, has shown remarkable potential in treating depression, with 70% of participants experiencing significant symptom relief after just one session. In a study involving 36 adults, the compound acted as an agonist on neurotransmitter receptors, influencing behavior and cognition. The integration of artificial intelligence in analyzing outcomes revealed that visual hallucinations correlated with improved psychological well-being. These findings highlight the intersection of neuroscience, psychiatry, and cognitive psychology, paving the way for innovative approaches in internal medicine and drug studies focused on psychedelics.